The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part Two
KOLs Provide the “Voice of the Patient” for Life-changing Discoveries According to the Pharmaceutical Research and Manufacturers of America (PhRMA—(http://www.phrma.org/), “Only one of every 10,000 potential medicines investigated by America’s research-based pharmaceutical companies makes it through the research and development pipeline and is approved for patient use by the United States Food and Drug Administration.” …
The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part Two Read More »
